复星医药4月7日公告,控股子公司复星医药(徐州)有限公司近日收到国家药品监督管理局关于同意CMC-2310口溶膜用于成人及13岁以上儿童患者的精神分裂症治疗开展临床试验的批准。CMC-2310为本集团自主研发的化学药品,拟用于成人及13岁以上儿童患者的精神分裂症治疗。截至2025年3月,本集团现阶段针对CMC-2310的累计研发投入约为人民币725万元(未经审计)。同活性成分的药物系2024年于...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.